首页> 外文期刊>Inflammatory bowel diseases >Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation.
【24h】

Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation.

机译:CXCL10在炎性肠病中的增强表达:黏膜Toll样受体3刺激的潜在作用。

获取原文
获取原文并翻译 | 示例
           

摘要

We explored the gene expression in colonic biopsies of active and inactive inflammatory bowel disease (IBD) in an extensive material of ulcerative colitis (UC) and Crohn's disease (CD). The chemokine CXCL10 and its receptor CXCR3 were among the upregulated genes. This study examined the expression of CXCL10 and the mechanisms for its release in patients with UC or CD and in intestinal epithelial cell (IEC) lines.A microarray gene expression analysis was done on colonic biopsies (n = 133) from patients with IBD. Biopsies were studied with immunohistochemistry for CXCL10 and CXCR3 expression. Mechanisms for CXCL10 release in peripheral blood mononuclear cells (PBMCs) and in the colonic epithelial cell lines HT-29 and SW620 were studied upon pattern recognition receptor (PRR) stimulation.CXCL10 and CXCR3 mRNA abundances were increased in biopsies from active UC and CD compared to inactive disease and controls. CXCL10 was mainly localized to mucosal epithelial cells, with increased immunostaining in active IBD. CXCR3-positive cells were scattered in the lamina propria. CXCL10 was secreted from the colonic epithelial cell lines in response to the Toll-like receptor 3 (TLR3) ligand polyinosinic: polycytidylic acid (poly(I:C)). This ligand also induced a marked release of CXCL10 in PBMCs from IBD patients and controls.We identified CXCL10 and CXCR3 as upregulated genes in colonic mucosa in active IBD. The TLR3-ligand poly(I:C) markedly increased release of CXCL10 in colonic epithelial cell lines, suggesting a TLR3-mediated CXCL10 release from mucosal epithelial cells in IBD patients.
机译:我们探讨了溃疡性结肠炎(UC)和克罗恩氏病(CD)的广泛材料中活动性和非活动性炎症性肠病(IBD)在结肠活检中的基因表达。趋化因子CXCL10及其受体CXCR3属于上调基因。这项研究检查了UC或CD患者以及肠上皮细胞(IEC)细胞系中CXCL10的表达及其释放机制。对IBD患者的结肠活检(n = 133)进行了微阵列基因表达分析。用免疫组织化学对CXCL10和CXCR3的表达进行活检。在模式识别受体(PRR)刺激下研究了外周血单个核细胞(PBMC)和结肠上皮细胞系HT-29和SW620中CXCL10释放的机制。活体UC和CD活检中CXCL10和CXCR3 mRNA的丰度增加不活跃的疾病和控制。 CXCL10主要位于黏膜上皮细胞,在活动性IBD中的免疫染色增加。 CXCR3阳性细胞散在固有层中。响应Toll样受体3(TLR3)配体多肌苷酸:聚胞苷酸(poly(I:C))从结肠上皮细胞系分泌CXCL10。该配体还诱导了IBD患者和对照的PBMC中CXCL10的明显释放。我们确定CXCL10和CXCR3是活动性IBD结肠黏膜中的上调基因。 TLR3配体聚(I:C)在结肠上皮细胞系中显着增加CXCL10的释放,这表明IBD患者中TLR3介导的CXCL10从粘膜上皮细胞的释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号